Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
Abroad (travel likely)Recruiting
Conditions
Colo-rectal Cancer (dMMR/MSI-H CRC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Undefined, China